Atropos Health is the leader in providing physicians with research-grade real-world evidence at the point of care.
A Prognostram usually answers even complicated medical questions in less than 24 hours, pulling from the latest research-grade data in an ever-growing expansive database. This allows for faster, more accurate care delivery directly at the bedside. The use of the Prognostogram will also drive personalization, health equity, and evidence-driven medicine through its use, as it pulls from data sets that can be easily customized to match patient demographics such as sex, race, age, and income to ensure more accurate care delivery. Further, research conducted using more diverse data sets will yield more accurate, inclusive results, as the data sets are based on a broad spectrum of very real, diverse patient populations.
Observational research is a broad category of clinical studies conducted as patient care is delivered, using actual patients who are receiving care and recording the results. This is one of the major pathways toward developing new care practices. Every year, thousands of these are published in peer-reviewed journals and subsequently adopted in clinical practice. The other pathway is constructed randomized controlled trials (RCTs) – these are traditional trials that utilize a control group and a random patient population. Physicians are asked to make decisions daily using the results of observational research and RCTs. Yet, Observational research can take 9-12 months to publish, and RCTs often exclude some of the most important populations worth studying, like racial minorities, pregnant women, those with lower income, children, and patients living in rural areas. As a result, a published RCT study may not apply to the needs of a specific patient who falls into one of these populations. The Prognostorgam aims to utilize research as it emerges and fill in gaps with relevant data from millions of anonymized patient records. As the EHR gathers data, the goal is to make it actionable immediately as patterns emerge, so patients receive the most personalized, up-to-date care.
Value to date is seen across diverse categories. The use of Prognostrograms across a dozen research publications shortened the time to a manuscript from 8-12 months to 2-3 weeks, saving $300,000 annually. Drug cost and procedural savings have been projected across transplant, cardiac, and infectious disease studies at almost $2M. Finally, by providing proof of concept data for a new initiative in the ICU, care for over 1000 patients has been impacted at a cost savings of over $3M. In addition to these studies, Atropos Prognostograms have provided the data analysis for several peer-reviewed publications, including articles in JAMA Otolaryngology, OFID, Journal of Clinical Oncology, and JACC with topics ranging from sleep apnea to breast cancer to therapies for heart conditions and infectious diseases.